Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026Unaudited cash ...

Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose ...

Under the agreement, MediLink will receive upfront and near-term milestone payments totalling $570m.

The company also announced the appointment of Han Lee, Ph.D., as co-chief executive officer (CEO), and the U.S. Food and Drug ...

Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare ...

Women who received Elenagen plus chemotherapy lived significantly longer than those who received chemotherapy alone.

In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments that could reach a combined $570 million. The Thursday evening release also ...

In my marketing class, one of the examples I use to illustrate the activities of competitors is a scenario of a young man ...

The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m ...

DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic ...

Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...